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The first pneumococcal conjugate vaccine (PCV7)
included 7 serotypes and was licensed for the use in
infants and in children < 5 years. Recently, preparations
containing a greater number of pneumococcal serotypes
have been developed and one of them, that including
the greatest number of serotypes (PCV13), has been
licensed for the use in older children and adolescents.
Compared to young children and the elderly, children
and adolescents aged 6-17 are at lower risk of pneumo-
coccal disease. Disease incidence falls markedly after the
second year and reaches its lowest point in adolescence.
Moreover, also carriage of Streptococcus pneumoniae
(Sp) also declines as children reaches adolescence.
Consequently, it is thought that vaccination of older
children and adolescents could only marginally reduce
the number of Sp disease in these subjects and poorly
contribute toward herd immunity for unvaccinated indi-
viduals. However, some recent data regarding carrier
state of healthy older children and adolescents vacci-
nated with PCV7 during infancy and living in areas with
vaccination coverage lower than 70% seem to suggest
that, at least in some particular situations, Sp carriage
can be higher than expected and regard most of the ser-
otypes included in the vaccine. This could indicate that
mucosal protection offered by PCV7 wanes in time and
that after some years, vaccinated children when exposed
to serotypes included in the vaccine can be re-colonized
with these serotypes and become potential source of
infection for unvaccinated subjects. Vaccination with
PCV13 could be useful to reduce this risk. However, the
most striking evidence of the potential beneficial effect
of vaccination with PCV13 of older children and adoles-
cents regards the so called subjects at risk. There is a
not marginal number of subjects 6-17 years old with
chronic heart, kidney, liver and respiratory disease, dia-
betes, cochlear implants or cerebrospinal fluid leaks,
functional or anatomic asplenia or immunosuppression
for whom an increased risk of severe pneumococcal dis-
ease is demonstrated or rationally supposed. In these
subjects, administration of PCV13 is today strongly
recommended, with different schedules according to the
previous use of the 23-valent polysaccharide vaccine
(PP23). On the other hand, PP23, since long time sug-
gested for protection of subjects at risk >2 years of age,
has several problems including an absolute poorer
immune response to common serotypes in comparison
to PCV13, an hyporesponsiveness to repeated doses, and
an uncertain efficacy in risk groups.
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